Sign in Check my fit
EN
Home / Horizon Europe / HORIZON-JU-IHI-2026-13-two-stage-03

Decode the Immunoscience of age-related diseases

Open now · HORIZON JU Research and Innovation Actions · two-stage · HORIZON-JU-IHI-2026-13-two-stage-03

Next cut-off
08 Oct '26
in 32 days
Per grant
€53M
the call's own average
Grants expected
1
projects that will be funded
Funding rate
100%
the full cost of the action

In context of Horizon Europe

This grant€53M
The track runs to the largest grant in Horizon Europe (€171M). The median across the 482 calls we publish is €5.3M, this one is above it.

What this call funds

Expected Impact:

The action under this topic is expected to achieve the following impacts:

  • Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases.
  • Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors.
  • Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention.
  • Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway.
  • Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator.
  • Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’.
  • Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities.
  • Enable new data-driven research by building AI infrastructure on existing data and cohorts that no single organisation could develop independently

Patients and citizens will benefit from improved medical practice and healthcare solutions, new targeted prevention strategies and ultimately healthier ageing.

The action will support EU policy and priorities including the European Health Data Space Regulation (EHDS) and the EU Artificial Intelligence Act, while contributing to European competitiveness in addressing one of society's major challenges.

Expected Outcome:

Trimmed here, the full scope, expected outcomes and award criteria are on the official topic page ↗.

Cut-offs

Later cut-off21 Apr 2027

What applying costs you

ItemEstimateNote
Drafting effort8–10 weeksshort proposal, then a full one
Partner search4–8 weeksruns in parallel, and it is the part that slips
Time to first payment9–12 monthscut-off → evaluation → grant agreement

These are Bemzu's estimates from the call's structure (the number of stages and whether a consortium is required) not figures published by the Commission. Only the co-financing share is read from the call itself.

Where these conditions come from

Two kinds of row. Most are the sentence we read the condition from, quoted out of the call itself. Some say plainly that they are not a quotation but the programme's own rule for this type of action, the EU portal publishes a table of contents where the conditions should be, so for a Research and Innovation Action the rate comes from the rulebook rather than from the fiche.

ConditionQuoted from the call, or the rule behind it
Consortium sizeNot quoted from this call — Research and Innovation Actions under the Horizon Europe rules are at least three independent legal entities from three different Member States or Associated Countries, at least one established in a Member State.
Funding rateNot quoted from this call — Research and Innovation Actions under the Horizon Europe rules are funded at 100% of eligible costs for every participant.

Also open in HE

Become the beneficiary.

Eight questions, no account, nothing sent anywhere. You will know which of the 1526 open calls you can actually enter before you finish your coffee.

Check my fit